Amazon affiliate link
Alcohol pads
MED PRIDE, 70% isopropyl, 200 count per listing. An alcohol pad does not establish sterility of a research product.
View on Amazon ↗Metabolic and cellular research
Retatrutide
research guide
Retatrutide is a compound from Eli Lilly that activates GIP, GLP-1 and glucagon receptors together. A phase 2, double-blind, randomized, placebo-controlled trial in 338 adults with obesity tested investigational retatrutide over 48 weeks; the 12mg group lost a mean 24.2% of body weight versus 2.1% with placebo, with dose-related gastrointestinal side effects [1]. This page summarizes that study, not the full development program. Supplier research vials are not the clinical trial drug product, and the trial does not establish their suitability for human use.
Evidence depends on population and formulation. Literature summary, not clinical peer review.
Looking for the product? Reign listings and business disclosure ↓
Jorge Abreu is not a doctor. This is an educational research summary, not a prescription or a personal dosing plan. Study results do not establish that a supplier product is safe or effective for people. Consult a licensed clinician about medical decisions.
01 · Start with identity
What is Retatrutide?
Retatrutide as studied by Eli Lilly is a proprietary, pharmaceutical-grade investigational compound dosed under monitored clinical trial protocols. Vials sold by peptide suppliers as research chemicals are separately synthesized by unrelated manufacturers; no publicly available data links their purity, formulation, or biological activity to the trial drug substance.
Also searched as: LY3437943, RT-3, triple GIP/GLP-1/glucagon receptor agonist
02 · Read the evidence
What the studies reported
01
Phase 2 dose-ranging weight loss results
At 48 weeks, mean body weight reductions were 8.7% in the 1mg group, 17.1% in the combined 4mg groups, 22.8% in the combined 8mg groups and 24.2% in the 12mg group, compared with 2.1% with placebo. The trial included different starting-dose strategies; not every group escalated. These are outcomes of supervised clinical research, not a suggested schedule for supplier products. [1]
02
Adverse events and heart rate
The most common adverse events across retatrutide groups were gastrointestinal, were dose-related, were mostly mild to moderate, and were partially reduced by using a lower starting dose; dose-dependent increases in heart rate peaked at 24 weeks and declined afterward. [1]
03 · Numbers in context
What does dosing evidence actually support?
The dosing schedule with controlled clinical evidence in the sources reviewed for this page comes from the single published phase 2 trial cited here, which randomized adults with obesity to weekly subcutaneous doses of 1mg, 4mg, 8mg or 12mg (with lower initial doses for the 4mg, 8mg and 12mg arms) or placebo for 48 weeks under study-drug conditions with medical monitoring [1]. This describes what was studied in that specific controlled trial population; it used Lilly's investigational drug substance, not a peptide vial from a research supplier, and does not establish a general protocol.
A study dose is not a personal dose. Population, route, formulation and supervision are part of the result. Online community schedules are not treated here as established clinical protocols.
04 · Safety and limits
What not to overlook
- Retatrutide is not FDA approved for any use; the trial cited here is one phase 2 study, and this page does not claim to summarize the compound's full trial program.
- Research vials sold under this or a similar name have no established identity or purity match to the clinical trial drug substance.
- The cited trial reported dose-related gastrointestinal adverse events and dose-dependent, transient increases in heart rate.
- Safety and efficacy beyond the 48-week trial window reviewed here were not assessed in the source cited.
05 · Product distinctions
Names are not interchangeable
The trial drug was a Lilly-manufactured investigational subcutaneous injectable administered under a clinical protocol. Products sold by peptide suppliers as lyophilized powder vials, for example labeled Reta RT-3, are separate, unapproved research chemicals sold for laboratory research use only; no bioequivalence, identity confirmation, or chain of custody to the trial compound has been established in the sources reviewed.
06 · Handling and storage
Follow validated product instructions
A single water volume, refrigerator temperature or expiry window cannot be assumed for every compound and formulation. Use the exact manufacturer documentation and a validated laboratory procedure. If stability, solvent compatibility or microbiological quality is not documented, those properties remain unverified.
Refrigeration, clear appearance and bacteriostatic water do not make an unverified research product suitable for injection. This guide does not provide a mixing or administration procedure.
The existing concentration calculator checks arithmetic only. It cannot choose a safe dose or establish compatibility, sterility or shelf life.
Reign Peptide · Business disclosure
Research product listings
Jorge Abreu is involved in Reign Peptide. Links to Reign are a business connection, not an independent endorsement. Reign lists these products for laboratory research, not human consumption.
Use the listing to check the labeled identity, amount and available batch documentation. A purity result alone does not verify sterility, clinical suitability or equivalence to a medicine used in a trial.
Names and sizes are product labels, not dosing recommendations. Confirm current details with the seller.
Supplies and accessories
Compare the actual specifications
Jorge's supply directory includes syringes, alcohol pads, storage cases, travel refrigeration and electrolytes, with separate links for the two travel refrigeration options. Accessory availability is not a recommendation to administer a research compound.
Affiliate disclosure: As an Amazon Associate I earn from qualifying purchases.
Amazon affiliate link
Peptide fridge case
Listing: 63 slots for 3mL bottles, bag only. An organizer is not active refrigeration or a validated storage system.
View on Amazon ↗Amazon affiliate link
Peptide travel case
Medineed travel case with temperature display and two ice packs per listing. Check dimensions and transport requirements.
View on Amazon ↗Questions still worth asking
What remains unresolved?
- What do longer-duration and later-phase trials of retatrutide show for cardiometabolic outcomes beyond the 48-week phase 2 window reviewed here?
- How does the composition of unapproved retatrutide-labeled research vials compare to the studied drug substance, and has this been independently tested?
Check the source
References and evidence scope
These are the sources reviewed for this page, not an exhaustive systematic review. Related compound research is identified as such. Product links are not scientific references.
Keep reading